| 000 | 01807 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513140317.0 | ||
| 264 | 0 | _c19980326 | |
| 008 | 199803s 0 0 eng d | ||
| 022 | _a0028-4793 | ||
| 024 | 7 |
_a10.1056/NEJM199803263381301 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPalella, F J | |
| 245 | 0 | 0 |
_aDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cMar 1998 |
||
| 300 |
_a853-60 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xepidemiology |
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xepidemiology |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aDrug Utilization _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInsurance, Health |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycobacterium avium-intracellulare Infection _xepidemiology |
| 650 | 0 | 4 |
_aPneumonia, Pneumocystis _xepidemiology |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 700 | 1 | _aDelaney, K M | |
| 700 | 1 | _aMoorman, A C | |
| 700 | 1 | _aLoveless, M O | |
| 700 | 1 | _aFuhrer, J | |
| 700 | 1 | _aSatten, G A | |
| 700 | 1 | _aAschman, D J | |
| 700 | 1 | _aHolmberg, S D | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 338 _gno. 13 _gp. 853-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJM199803263381301 _zAvailable from publisher's website |
| 999 |
_c9483975 _d9483975 |
||